CellEngine Auto-Gate: Accurate Gating in COVID Study

May 22, 2023

Anita L. Ray, Susan Reynolds, Zach Bjornson, Martin Tolstrup, Angela M. Cheung, Eustache Paramithiotis

CellCarta’s poster demonstrates the effectiveness of CellEngine’s automatic gate adjustment tool in cytometry analysis for a COVID-19 longitudinal clinical study. The tool uses a machine-learning algorithm trained on manually gated samples to automatically gate large datasets, significantly reducing analysis time while maintaining accuracy.

The study focused on two markers, CCR5 and perforin, known for high variability, and showed that the tool produced results highly similar to manual gating, with a time reduction of 69.3% for perforin and 88.5% for CCR5

View the full poster:

CellEngine’s automatic gate adjustment tool quickly and accurately recapitulates manual gating: assessment in a COVID longitudinal clinical study

As presented in CYTO2023

CellEngine’s automatic gate adjustment tool quickly and accurately recapitulates manual gating: assessment in a COVID longitudinal clinical study

Autogating

  • Closely correlates with manual gating
  • Reduces analysis time by 69% to 89%
  • Adjusts gates for thousands of files in seconds
  • Full deterministic operation based on a few manually gated files

CellEngine Auto-Gate: Accurate Gating in COVID Study

May 22, 2023

Anita L. Ray, Susan Reynolds, Zach Bjornson, Martin Tolstrup, Angela M. Cheung, Eustache Paramithiotis

CellCarta’s poster demonstrates the effectiveness of CellEngine’s automatic gate adjustment tool in cytometry analysis for a COVID-19 longitudinal clinical study. The tool uses a machine-learning algorithm trained on manually gated samples to automatically gate large datasets, significantly reducing analysis time while maintaining accuracy.

The study focused on two markers, CCR5 and perforin, known for high variability, and showed that the tool produced results highly similar to manual gating, with a time reduction of 69.3% for perforin and 88.5% for CCR5

View the full poster:

CellEngine’s automatic gate adjustment tool quickly and accurately recapitulates manual gating: assessment in a COVID longitudinal clinical study

As presented in CYTO2023

CellEngine’s automatic gate adjustment tool quickly and accurately recapitulates manual gating: assessment in a COVID longitudinal clinical study

Autogating

  • Closely correlates with manual gating
  • Reduces analysis time by 69% to 89%
  • Adjusts gates for thousands of files in seconds
  • Full deterministic operation based on a few manually gated files

T-Cell Response in COVID-19 Vaccine Development- A Webinar by CellCarta

October 1, 2020

Discussions on COVID-19 immune responses, including the responses in early vaccine clinical studies, have focused largely on antibody responses.

However, recent data indicate that the cellular immune response also plays an important role and should be considered when evaluating the immune response.

Assessing T-cell responses can provide critical information about vaccine responses and the development and persistence of protective immunity against SARS-CoV-2 that will be critical in the fight against COVID-19.

The webinar is co-sponsored by Caprion-HistoGeneX  and WCG and will feature the following speakers:

author photo

Scott Gottlieb, M.D., Former Commissioner of the Food and Drug Administration (FDA)
Dr. Gottlieb will discuss the implications of immune response testing for overall assessment, regulatory approval, and public acceptance of COVID-19 vaccines.

author photo

James Rothman, Ph.D., Sterling Professor of Cell Biology, Yale University; Recipient, Nobel Prize in Medicine, 2013
Dr. Rothman will provide an overview of the immune response to SARS-CoV-2 and the importance of cellular immunity. The key findings from our previous experiences with SARS-CoV-1 as well as the latest publications will also be discussed.

author photo

Eustache Paramithiotis, Ph.D., Vice President, Research & Development, Caprion-HistoGeneX
Testing methods for understanding complex immune system reactions as part of vaccine development programs will be discussed by Dr. Paramithiotis. Information on the methodology and accuracy of these assays will be provided.

Our speakers will discuss:

  • An overview of the current state of COVID-19 vaccine development
  • The adaptive immune response to SARS-CoV-2 and the importance of cellular immunity
  • Testing methods and assay standardization for understanding complex immune system reactions as part of vaccine development programs

Learn more about CellCarta

T-Cell Response in COVID-19 Vaccine Development- A Webinar by CellCarta

October 1, 2020

Discussions on COVID-19 immune responses, including the responses in early vaccine clinical studies, have focused largely on antibody responses.

However, recent data indicate that the cellular immune response also plays an important role and should be considered when evaluating the immune response.

Assessing T-cell responses can provide critical information about vaccine responses and the development and persistence of protective immunity against SARS-CoV-2 that will be critical in the fight against COVID-19.

The webinar is co-sponsored by Caprion-HistoGeneX  and WCG and will feature the following speakers:

author photo

Scott Gottlieb, M.D., Former Commissioner of the Food and Drug Administration (FDA)
Dr. Gottlieb will discuss the implications of immune response testing for overall assessment, regulatory approval, and public acceptance of COVID-19 vaccines.

author photo

James Rothman, Ph.D., Sterling Professor of Cell Biology, Yale University; Recipient, Nobel Prize in Medicine, 2013
Dr. Rothman will provide an overview of the immune response to SARS-CoV-2 and the importance of cellular immunity. The key findings from our previous experiences with SARS-CoV-1 as well as the latest publications will also be discussed.

author photo

Eustache Paramithiotis, Ph.D., Vice President, Research & Development, Caprion-HistoGeneX
Testing methods for understanding complex immune system reactions as part of vaccine development programs will be discussed by Dr. Paramithiotis. Information on the methodology and accuracy of these assays will be provided.

Our speakers will discuss:

  • An overview of the current state of COVID-19 vaccine development
  • The adaptive immune response to SARS-CoV-2 and the importance of cellular immunity
  • Testing methods and assay standardization for understanding complex immune system reactions as part of vaccine development programs

Learn more about CellCarta

Soluble plasma HLA peptidome as a potential source for CHB biomarkers

July 29, 2019

Diana Chen, Ruidong Li, Eustache Paramithiotis, Gwen Pottiez, Ross Martin, Xinan Liu, Jenny Svarovskaia, Hongmei Mo, Li Li, Anuj Gaggar, Jeffrey Wallin

Soluble plasma HLA peptidome as a potential source for CHB biomarkers, AASLD 2019

Soluble plasma HLA peptidome as a potential source for CHB biomarkers

Soluble plasma HLA peptidome as a potential source for CHB biomarkers

July 29, 2019

Diana Chen, Ruidong Li, Eustache Paramithiotis, Gwen Pottiez, Ross Martin, Xinan Liu, Jenny Svarovskaia, Hongmei Mo, Li Li, Anuj Gaggar, Jeffrey Wallin

Soluble plasma HLA peptidome as a potential source for CHB biomarkers, AASLD 2019

Soluble plasma HLA peptidome as a potential source for CHB biomarkers

Biomarkers associated with ALT flares in HBsAg decline in patients with chronic hepatitis B

July 29, 2019

Jeffrey Wallin, Diana Chen, Ruidong Li, Vithika Suri, Don Kang, Sam Kim, Eustache Paramithiotis, Gwen Pottiez, Li Li, Anuj Gaggar.

Biomarkers associated with ALT flares in HBsAg decline in patients with chronic hepatitis B, AASLD 2019.

Biomarkers associated with ALT flares in HBsAg decline in patients with chronic hepatitis B

Biomarkers associated with ALT flares in HBsAg decline in patients with chronic hepatitis B

July 29, 2019

Jeffrey Wallin, Diana Chen, Ruidong Li, Vithika Suri, Don Kang, Sam Kim, Eustache Paramithiotis, Gwen Pottiez, Li Li, Anuj Gaggar.

Biomarkers associated with ALT flares in HBsAg decline in patients with chronic hepatitis B, AASLD 2019.

Biomarkers associated with ALT flares in HBsAg decline in patients with chronic hepatitis B

Protein Biomarkers Dengue Vaccine

June 9, 2018

V. Hindie¹, P. Croteau¹, S. Aziri¹, S. Lo¹, J. Sui¹, L. Cortes¹, E. Kallas², R.P. Sekaly³, and E. Paramithiotis¹. ¹Caprion Biosciences Inc, Montreal, QC, Canada. ²School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. ³Case Western Reserve University, Cleveland, OH, USA. VH, PC, SA, SL, JS, LC, and EP are employees of Caprion Biosciences Inc.

Protein Biomarkers Predictive of Multivalent Response to a Novel Dengue Vaccine, European Congress of Immunology, 2018

Protein biomarkers predictive of multivalent response to a novel dengue vaccine

Protein Biomarkers Dengue Vaccine

June 9, 2018

V. Hindie¹, P. Croteau¹, S. Aziri¹, S. Lo¹, J. Sui¹, L. Cortes¹, E. Kallas², R.P. Sekaly³, and E. Paramithiotis¹. ¹Caprion Biosciences Inc, Montreal, QC, Canada. ²School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. ³Case Western Reserve University, Cleveland, OH, USA. VH, PC, SA, SL, JS, LC, and EP are employees of Caprion Biosciences Inc.

Protein Biomarkers Predictive of Multivalent Response to a Novel Dengue Vaccine, European Congress of Immunology, 2018

Protein biomarkers predictive of multivalent response to a novel dengue vaccine